应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SUPN Supernus Pharmaceuticals
休市中 05-17 16:00:00 EDT
29.10
-0.06
-0.21%
盘后
29.10
+0.00
0.00%
16:02 EDT
最高
29.32
最低
28.70
成交量
62.54万
今开
29.32
昨收
29.16
日振幅
2.13%
总市值
16.00亿
流通市值
13.95亿
总股本
5,497万
成交额
1,814万
换手率
1.30%
流通股本
4,795万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元,同比减少99.27%
自选股智能写手 · 05-18 00:07
Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元,同比减少99.27%
Supernus Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报28.45美元
自选股智能写手 · 05-10
Supernus Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报28.45美元
Supernus 制药公司公布截至三月份的季度业绩 - 收益摘要
Reuters · 05-10
Supernus 制药公司公布截至三月份的季度业绩 - 收益摘要
Supernus Pharmaceuticals, Inc.盘中异动 大幅拉升7.17%
自选股智能写手 · 04-23
Supernus Pharmaceuticals, Inc.盘中异动 大幅拉升7.17%
嗡嗡声--美国股票走势-Ocugen、N 型、Fastly
Reuters · 04-08
嗡嗡声--美国股票走势-Ocugen、N 型、Fastly
Supernus Pharmaceuticals, Inc.盘中异动 大幅跳水7.14%
自选股智能写手 · 04-08
Supernus Pharmaceuticals, Inc.盘中异动 大幅跳水7.14%
BUZZ-美国食品和药物管理局(FDA)拒绝批准 Supernus 的帕金森病药物-器械组合疗法,导致 Supernus 业绩下滑
Reuters · 04-08
BUZZ-美国食品和药物管理局(FDA)拒绝批准 Supernus 的帕金森病药物-器械组合疗法,导致 Supernus 业绩下滑
Supernus Pharmaceuticals, Inc.盘中异动 急速下挫5.10%报32.76美元
自选股智能写手 · 03-26
Supernus Pharmaceuticals, Inc.盘中异动 急速下挫5.10%报32.76美元
Supernus Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.04%
自选股智能写手 · 03-14
Supernus Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.04%
Supernus Pharmaceuticals, Inc.2023财年实现净利润1.32百万美元,同比减少97.83%
自选股智能写手 · 03-03
Supernus Pharmaceuticals, Inc.2023财年实现净利润1.32百万美元,同比减少97.83%
Supernus Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.08%报31.21美元
自选股智能写手 · 03-02
Supernus Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.08%报31.21美元
Supernus Pharmaceuticals Inc盘中异动 股价大跌6.22%报28.78美元
自选股智能写手 · 02-28
Supernus Pharmaceuticals Inc盘中异动 股价大跌6.22%报28.78美元
美国研究综述-Autozone、Constellation Energy、Sterling Infrastructure
Reuters · 02-28
美国研究综述-Autozone、Constellation Energy、Sterling Infrastructure
Supernus 制药公司公布截至 12 月的季度业绩 - 收益摘要
Reuters · 02-28
Supernus 制药公司公布截至 12 月的季度业绩 - 收益摘要
Supernus Pharmaceuticals Inc盘中异动 急速上涨5.05%报30.99美元
自选股智能写手 · 02-28
Supernus Pharmaceuticals Inc盘中异动 急速上涨5.05%报30.99美元
Supernus Pharmaceuticals Inc 预计每股收益55美分 - 财报前瞻
Reuters · 02-24
Supernus Pharmaceuticals Inc 预计每股收益55美分 - 财报前瞻
Supernus Pharmaceuticals Inc盘中异动 下午盘大幅下挫5.04%报26.92美元
自选股智能写手 · 02-14
Supernus Pharmaceuticals Inc盘中异动 下午盘大幅下挫5.04%报26.92美元
Supernus Pharmaceuticals Inc盘中异动 早盘快速上涨6.29%报29.41美元
自选股智能写手 · 01-22
Supernus Pharmaceuticals Inc盘中异动 早盘快速上涨6.29%报29.41美元
加载更多
公司概况
公司名称:
Supernus Pharmaceuticals
所属市场:
NASDAQ
上市日期:
--
主营业务:
Supernus Pharmaceuticals, Inc.于2005年3月30日在美国特拉华州注册成立,并于2005年12月22日开始运营。该公司是一家专业制药公司,专注于开发和商业化产品,为治疗中枢神经系统疾病,包括神经和精神治疗紊乱。公司有两个专利产品和几个专有候选产品的临床开发,可满足癫痫症和注意力缺陷多动障碍的市场需求。
发行价格:
--
{"stockData":{"symbol":"SUPN","market":"US","secType":"STK","nameCN":"Supernus Pharmaceuticals","latestPrice":29.1,"timestamp":1715976000000,"preClose":29.16,"halted":0,"volume":625388,"hourTrading":{"tag":"盘后","latestPrice":29.1,"preClose":29.1,"latestTime":"16:02 EDT","volume":7758,"amount":225757.16,"timestamp":1715976134608},"delay":0,"floatShares":47945421,"shares":54974254,"eps":-0.303905,"marketStatus":"休市中","marketStatusCode":7,"change":-0.06,"latestTime":"05-17 16:00:00 EDT","open":29.32,"high":29.32,"low":28.7,"amount":18139071.874492,"amplitude":0.021262,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.303905,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1716192000000},"adr":0,"listingDate":1335844800000,"adjPreClose":29.16,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":29.1,"preClose":29.1,"latestTime":"16:02 EDT","volume":7758,"amount":225757.16,"timestamp":1715976134608},"volumeRatio":0.8931911931301912},"requestUrl":"/m/hq/s/SUPN/","defaultTab":"news","newsList":[{"id":"2436365946","title":"Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元,同比减少99.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436365946","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436365946?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:07","pubTimestamp":1715962078,"startTime":"0","endTime":"0","summary":"3月31日,Supernus Pharmaceuticals, Inc.公布财报,公告显示公司2024财年第一财季净利润为124000.00美元,同比减少99.27%;其中营业收入为1.44亿美元,同比减少6.49%,每股基本收益为0.00美元。机构评级:截至2024年3月31日,当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测,其中目标均价为40.50美元,其中最低目标价为38.00美元,最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434507628","title":"Supernus Pharmaceuticals, Inc.盘中异动 股价大跌5.17%报28.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434507628","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434507628?lang=zh_cn&edition=full","pubTime":"2024-05-10 22:46","pubTimestamp":1715352377,"startTime":"0","endTime":"0","summary":"北京时间2024年05月10日22时46分,Supernus Pharmaceuticals, Inc.股票出现波动,股价大幅下跌5.17%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.32%。其相关个股中,Organogenesis Holdings Inc.、Sunshine Biopharma Inc C/Wts 、Cyclo Therapeutics, Inc.涨幅较大,Sunshine Biopharma Inc.、Pacira Biosciences, Inc.、苏轩堂较为活跃,换手率分别为91.93%、8.75%、7.33%,振幅较大的相关个股有Organogenesis Holdings Inc.、Biofrontera Inc.、Clever Leaves Holdings Inc.,振幅分别为26.54%、24.05%、17.00%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102246177a5942e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102246177a5942e3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434048695","title":"Supernus 制药公司公布截至三月份的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2434048695","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2434048695?lang=zh_cn&edition=full","pubTime":"2024-05-10 00:56","pubTimestamp":1715273777,"startTime":"0","endTime":"0","summary":" * Supernus Pharmaceuticals Inc 报告了截至3月底的季度调整后每股收益26美分,低于去年同期的每股收益29美分。四位分析师对该季度的平均预期是每股收益 38 美分。华尔街预期为每股收益 29 美分至 48 美分。* Supernus Pharmaceuticals Inc 公布的本季度每股收益为盈亏平衡。* 该公司报告的季度净收入为 12.4 万美元。* Supernus Pharmaceuticals Inc 的股价本季度下跌了 8.2%,今年迄今为止上涨了 8.2%。* 医药同行的平均一致建议也是 \"买入\"。华尔街对 Supernus Pharmaceuticals Inc 的 12 个月目标价中位数为 40.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429185761","title":"Supernus Pharmaceuticals, Inc.盘中异动 大幅拉升7.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429185761","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429185761?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:30","pubTimestamp":1713879030,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日21时30分,Supernus Pharmaceuticals, Inc.股票出现异动,股价大幅拉升7.17%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体涨幅为0.78%。其相关个股中,Procaps Group, S.A.、Supernus Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.涨幅较大,Sunshine Biopharma Inc.、苏轩堂、Petros Pharmaceuticals, Inc.较为活跃,换手率分别为91.13%、4.20%、3.68%,振幅较大的相关个股有Supernus Pharmaceuticals, Inc.、Evotec Se、Canopy Growth Corporation,振幅分别为7.03%、2.58%、2.04%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130317922ae9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130317922ae9e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425224990","title":"嗡嗡声--美国股票走势-Ocugen、N 型、Fastly","url":"https://stock-news.laohu8.com/highlight/detail?id=2425224990","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425224990?lang=zh_cn&edition=full","pubTime":"2024-04-08 21:50","pubTimestamp":1712584215,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 4月8日 - 周一,由于对美国联邦储备委员会今年可能推迟降息的押注升温,国债收益率上升,追踪华尔街主要股指的期货市场基本表现平淡。美东时间9:23,道指电子盘 上涨0.13%,报39,274点。标准普尔500指数小型股 上涨0.22%,报5,264.75点;纳斯达克100指数小型股 上涨0.33%,报18,362点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2425908889","title":"Supernus Pharmaceuticals, Inc.盘中异动 大幅跳水7.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425908889","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425908889?lang=zh_cn&edition=full","pubTime":"2024-04-08 21:32","pubTimestamp":1712583123,"startTime":"0","endTime":"0","summary":"北京时间2024年04月08日21时32分,Supernus Pharmaceuticals, Inc.股票出现异动,股价快速下挫7.14%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.36%。其相关个股中,Organigram Holdings Inc.、Evotec Se、和黄医药涨幅较大,苏轩堂、Petros Pharmaceuticals, Inc.、阿索尔达生物较为活跃,换手率分别为13.19%、3.26%、2.56%,振幅较大的相关个股有阿索尔达生物、Im Cannabis Corp.、Esperion Therapeutics, Inc.,振幅分别为5.91%、4.65%、4.01%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082132038754a2b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082132038754a2b1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425312999","title":"BUZZ-美国食品和药物管理局(FDA)拒绝批准 Supernus 的帕金森病药物-器械组合疗法,导致 Supernus 业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2425312999","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425312999?lang=zh_cn&edition=full","pubTime":"2024-04-08 20:29","pubTimestamp":1712579354,"startTime":"0","endTime":"0","summary":" 4月8日 - ** Supernus Pharmaceuticals 股价盘前下跌10.6%至30美元** 该公司称 美国 FDA 拒绝批准其实验性阿朴吗啡输注装置的申请,该装置用于持续治疗帕金森病的运动波动。** 美国食品及药物管理局在信中称,该申请目前的形式还不具备获得批准的条件** FDA 提到两个方面需要额外的审查或信息** SUPN 最近向 FDA 提交了额外的产品质量数据,但 FDA 尚未对其进行审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422152025","title":"Supernus Pharmaceuticals, Inc.盘中异动 急速下挫5.10%报32.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422152025","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422152025?lang=zh_cn&edition=full","pubTime":"2024-03-26 03:17","pubTimestamp":1711394227,"startTime":"0","endTime":"0","summary":"北京时间2024年03月26日03时17分,Supernus Pharmaceuticals, Inc.股票出现异动,股价快速下跌5.10%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体涨幅为0.43%。其相关个股中,Scilex Holding Company C/Wts 10/11/2027 、Esperion Therapeutics, Inc.、Flora Growth Corp.涨幅较大,Flora Growth Corp.、Canopy Growth Corporation、Akanda Corp.较为活跃,换手率分别为233.79%、45.85%、30.27%,振幅较大的相关个股有Flora Growth Corp.、Scilex Holding Company C/Wts 10/11/2027 、Canopy Growth Corporation,振幅分别为35.44%、27.88%、26.92%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032603170787e7b8c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032603170787e7b8c3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419593516","title":"Supernus Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419593516","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419593516?lang=zh_cn&edition=full","pubTime":"2024-03-14 02:34","pubTimestamp":1710354869,"startTime":"0","endTime":"0","summary":"北京时间2024年03月14日02时34分,Supernus Pharmaceuticals, Inc.股票出现波动,股价大幅拉升5.04%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体跌幅为0.05%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140234307a4c5f33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403140234307a4c5f33&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416964788","title":"Supernus Pharmaceuticals, Inc.2023财年实现净利润1.32百万美元,同比减少97.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416964788","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416964788?lang=zh_cn&edition=full","pubTime":"2024-03-03 00:26","pubTimestamp":1709396808,"startTime":"0","endTime":"0","summary":"12月31日,Supernus Pharmaceuticals, Inc.公布财报,公告显示公司2023财年净利润为1.32百万美元,同比减少97.83%;其中营业收入为6.08亿美元,同比减少8.85%,每股基本收益为0.02美元。机构评级:截至2023年12月31日,当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测,其中目标均价为40.50美元,其中最低目标价为38.00美元,最高目标价为43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030300265187dceecc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030300265187dceecc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416334674","title":"Supernus Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.08%报31.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416334674","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416334674?lang=zh_cn&edition=full","pubTime":"2024-03-02 04:52","pubTimestamp":1709326375,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日04时52分,Supernus Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.08%。Supernus Pharmaceuticals, Inc.股票所在的制药行业中,整体涨幅为2.85%。Supernus Pharmaceuticals, Inc.公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。消息层面,截至04时52分,《Earnings Call Summary | Supernus Pharmaceuticals Q4 2023 Earnings Conference》资讯为影响Supernus Pharmaceuticals, Inc.的重要信息。Supernus Pharmicals预计,美国食品药品管理局将在4月批准SPN-830,并预计其首创分子将在未来12至18个月内实现多个临床里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030204525687e75530&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030204525687e75530&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415320082","title":"Supernus Pharmaceuticals Inc盘中异动 股价大跌6.22%报28.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415320082","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415320082?lang=zh_cn&edition=full","pubTime":"2024-02-28 22:32","pubTimestamp":1709130749,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日22时32分,Supernus Pharmaceuticals Inc股票出现异动,股价急速跳水6.22%。Supernus Pharmaceuticals Inc股票所在的制药行业中,整体跌幅为0.28%。Supernus Pharmaceuticals Inc公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。Supernus Pharmicals预计,美国食品药品管理局将在4月批准SPN-830,并预计其首创分子将在未来12至18个月内实现多个临床里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022822322987cccb7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022822322987cccb7e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414239243","title":"美国研究综述-Autozone、Constellation Energy、Sterling Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2414239243","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414239243?lang=zh_cn&edition=full","pubTime":"2024-02-28 15:20","pubTimestamp":1709104828,"startTime":"0","endTime":"0","summary":" 路透社2月28日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括 Autozone、Constellation Energy 和 Sterling Infrastructure。要闻 * Autozone Inc :杰富瑞将目标价从3100美元上调至3400美元 * Constellation Energy Corp :KeyBanc将目标价从行业权重上调至增持 * Sterling Infrastructure Inc :D.A.戴维森将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414330071","title":"Supernus 制药公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2414330071","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414330071?lang=zh_cn&edition=full","pubTime":"2024-02-28 08:14","pubTimestamp":1709079251,"startTime":"0","endTime":"0","summary":" * Supernus Pharmaceuticals Inc 报告了截至12月底的季度调整后每股收益89美分,高于去年同期的每股收益43美分。华尔街预期为每股收益 38 美分至 84 美分。* 营收同比下降 1.8%,至 1.6431 亿美元;分析师预期为 1.5503 亿美元。* Supernus Pharmaceuticals Inc公布的本季度每股收益为2美分。* 公司报告的季度净收入为 118 万美元。* Supernus Pharmaceuticals Inc 的股价本季度上涨了 1.9%。* 医药同行的平均一致建议也是 \"买入\"。华尔街对 Supernus Pharmaceuticals Inc 的 12 个月目标价中位数为 41.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414080215","title":"Supernus Pharmaceuticals Inc盘中异动 急速上涨5.05%报30.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414080215","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414080215?lang=zh_cn&edition=full","pubTime":"2024-02-28 00:25","pubTimestamp":1709051115,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日00时25分,Supernus Pharmaceuticals Inc股票出现波动,股价大幅上涨5.05%。截至发稿,该股报30.99美元/股,成交量27.0903万股,换手率0.50%,振幅5.14%。Supernus Pharmaceuticals Inc股票所在的制药行业中,整体跌幅为0.34%。Supernus Pharmaceuticals Inc公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402280025167a4757aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402280025167a4757aa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413742145","title":"Supernus Pharmaceuticals Inc 预计每股收益55美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2413742145","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413742145?lang=zh_cn&edition=full","pubTime":"2024-02-24 10:16","pubTimestamp":1708740989,"startTime":"0","endTime":"0","summary":" * Supernus Pharmaceuticals Inc 将于2月27日公布截至2023年12月31日的财报,预计该公司的季度收入将出现下降。* 根据LSEG的数据,4位分析师的平均预期显示,这家总部位于马里兰州罗克维尔的公司的营收将从去年同期的1.6733亿美元下降7.3%,至1.55031亿美元。* LSEG 分析师对 Supernus Pharmaceuticals Inc 的平均预期为每股收益 55 美分。* 华尔街对 Supernus Pharmaceuticals Inc 的 12 个月目标价中位数为 41.50 美元,高于其最新收盘价 29.06 美元。2月24日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411914963","title":"Supernus Pharmaceuticals Inc盘中异动 下午盘大幅下挫5.04%报26.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411914963","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411914963?lang=zh_cn&edition=full","pubTime":"2024-02-14 04:25","pubTimestamp":1707855905,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日04时25分,Supernus Pharmaceuticals Inc股票出现波动,股价大幅跳水5.04%。截至发稿,该股报26.92美元/股,成交量10.4879万股,换手率0.19%,振幅3.46%。Supernus Pharmaceuticals Inc股票所在的制药行业中,整体跌幅为0.39%。Supernus Pharmaceuticals Inc公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402140425067911461b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402140425067911461b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405890541","title":"Supernus Pharmaceuticals Inc盘中异动 早盘快速上涨6.29%报29.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2405890541","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2405890541?lang=zh_cn&edition=full","pubTime":"2024-01-22 22:37","pubTimestamp":1705934222,"startTime":"0","endTime":"0","summary":"北京时间2024年01月22日22时37分,Supernus Pharmaceuticals Inc股票出现波动,股价急速拉升6.29%。Supernus Pharmaceuticals Inc股票所在的制药行业中,整体涨幅为0.13%。其相关个股中,阿索尔达生物、Incannex Healthcare Inc、Neptune Wellness Solutions Inc涨幅较大,苏轩堂、Akanda Corp、Shuttle Pharmaceuticals Hldgs Inc较为活跃,换手率分别为0.85%、0.56%、0.55%,振幅较大的相关个股有Shuttle Pharmaceuticals Hldgs Inc、Supernus Pharmaceuticals Inc、Akanda Corp,振幅分别为11.54%、6.36%、5.67%。Supernus Pharmaceuticals Inc公司简介:Supernus Pharmaceuticals Inc 是一家专业制药公司,致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401222237027a3d4d10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401222237027a3d4d10&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.supernus.com","stockEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0034},{"period":"3month","weight":0.0239},{"period":"6month","weight":0.0609},{"period":"1year","weight":-0.1679},{"period":"ytd","weight":0.0055}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Supernus Pharmaceuticals, Inc.于2005年3月30日在美国特拉华州注册成立,并于2005年12月22日开始运营。该公司是一家专业制药公司,专注于开发和商业化产品,为治疗中枢神经系统疾病,包括神经和精神治疗紊乱。公司有两个专利产品和几个专有候选产品的临床开发,可满足癫痫症和注意力缺陷多动障碍的市场需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.06073},{"month":2,"riseRate":0.5,"avgChangeRate":-0.005563},{"month":3,"riseRate":0.5,"avgChangeRate":0.04471},{"month":4,"riseRate":0.666667,"avgChangeRate":0.029799},{"month":5,"riseRate":0.583333,"avgChangeRate":0.060484},{"month":6,"riseRate":0.75,"avgChangeRate":0.11448},{"month":7,"riseRate":0.583333,"avgChangeRate":0.020489},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019853},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.022081},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.022339},{"month":11,"riseRate":0.583333,"avgChangeRate":0.001299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013553}],"exchange":"NASDAQ","name":"Supernus Pharmaceuticals","nameEN":"Supernus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Supernus Pharmaceuticals,SUPN,Supernus Pharmaceuticals股票,Supernus Pharmaceuticals股票老虎,Supernus Pharmaceuticals股票老虎国际,Supernus Pharmaceuticals行情,Supernus Pharmaceuticals股票行情,Supernus Pharmaceuticals股价,Supernus Pharmaceuticals股市,Supernus Pharmaceuticals股票价格,Supernus Pharmaceuticals股票交易,Supernus Pharmaceuticals股票购买,Supernus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Supernus Pharmaceuticals(SUPN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Supernus Pharmaceuticals(SUPN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}